Related Experiment Video
Updated: Dec 28, 2025
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Future Therapeutic Directions for Smac-Mimetics
Emma Morrish1,2, Gabriela Brumatti1,2, John Silke1,2
1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia.
Abstract:
It is well accepted that the ability of cancer cells to circumvent the cell death program that untransformed cells are subject to helps promote tumor growth. Strategies designed to reinstate the cell death program in cancer cells have therefore been investigated for decades. Overexpression of members of the Inhibitor of APoptosis (IAP) protein family is one possible mechanism hindering the death of cancer cells. To promote cell death, drugs that mimic natural IAP antagonists, such as second mitochondria-derived activator of caspases (Smac/DIABLO) were developed. Smac-Mimetics (SMs) have entered clinical trials for hematological and solid cancers, unfortunately with variable and limited results so far. This review explores the use of SMs for the treatment of cancer, their potential to synergize with up-coming treatments and, finally, discusses the challenges and optimism facing this strategy.
Insights
Cancer cells evade death, promoting tumor growth. This review examines Smac-Mimetics (SMs) as a strategy to reinstate cell death, discussing their potential, synergy with other treatments, and challenges in cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer cells evade apoptosis, a programmed cell death pathway, contributing to tumor progression.
- Overexpression of Inhibitor of Apoptosis (IAP) proteins is a key mechanism cancer cells use to resist cell death.
- Second mitochondria-derived activator of caspases (Smac/DIABLO) antagonists, known as Smac-Mimetics (SMs), are designed to counteract IAPs and promote cancer cell death.
Purpose of the Study:
- To review the current applications of Smac-Mimetics (SMs) in cancer treatment.
- To explore the potential of SMs to synergize with emerging cancer therapies.
- To discuss the challenges and future prospects of SM-based cancer treatment strategies.
Main Methods:
- Literature review of studies on Smac-Mimetics (SMs) in cancer therapy.
- Analysis of clinical trial data for SMs in hematological and solid cancers.
- Exploration of mechanisms of action and resistance to SMs.
Main Results:
- Smac-Mimetics (SMs) have shown promise in preclinical and clinical settings but exhibit variable and limited efficacy in current trials.
- SMs have the potential to enhance the effectiveness of other anti-cancer treatments through synergistic interactions.
- Understanding resistance mechanisms is crucial for optimizing SM therapy.
Conclusions:
- Smac-Mimetics (SMs) represent a promising therapeutic strategy for cancer by targeting IAP proteins and restoring apoptosis.
- Further research and clinical investigation are needed to overcome current limitations and fully realize the potential of SMs in combination therapies.
- Optimizing SM delivery, combination strategies, and patient selection will be key to improving outcomes in cancer treatment.
